Rethinking the residual approach: Leveraging machine learning to operationalize cognitive resilience in Alzheimer’s disease

Colin Birkenbihl; Madison Cuppels; Rory T. Boyle; Hannah M. Klinger; Oliver Langford; Gillian T. Coughlan; Michael J. Properzi; Jasmeer Chhatwal; Julie T. Price; Aaron P. Schultz; Dorene M. Rentz; Rebecca E. Amariglio; Keith A. Johnson; Rebecca F. Gottesman; Shubhabrata Mukherjee; Paul Maruff; Yen Ying Lim; Colin L. Masters; Alexa Beiser; Susan M. Resnick; Timothy M. Hughes; Samantha Burnham; Ilke Tunali; Susan Landau; Ann D. Cohen; Sterling C. Johnson; Tobey J. Betthauser; Sudha Seshadri; Samuel N. Lockhart; Sid E. O’Bryant; Prashanthi Vemuri; Reisa A. Sperling; Timothy J. Hohman; Michael C. Donohue; Rachel F. Buckley

doi:10.1101/2024.08.19.24312256

Abstract

Cognitive resilience describes the phenomenon of individuals evading cognitive decline despite prominent Alzheimer’s disease neuropathology. Operationalization and measurement of this latent construct is non-trivial as it cannot be directly observed. The residual approach has been widely applied to estimate CR, where the degree of resilience is estimated through a linear model’s residuals. We demonstrate that this approach makes specific, uncontrollable assumptions and likely leads to biased and erroneous resilience estimates. We propose an alternative strategy which overcomes the standard approach’s limitations using machine learning principles. Our proposed approach makes fewer assumptions about the data and construct to be measured and achieves better estimation accuracy on simulated ground-truth data.

cognitive resilience
Alzheimer’s disease
dementia
machine learning
artificial intelligence
cognitive reserve
pathology resistance
cognitive decline

Competing Interest Statement

Paul Maruff is a full-time employee of Cogstate Ltd. Samuel N. Lockhart is a full time employee of Invicro LLC. SCJ has served in the past three years as a consultant to ALZPath and Enigma Biomedical.

Funding Statement

This project is supported by R01AG079142. Coughlan is funded by a NIH Pathway to Independence award, K99AG083063, and an Alzheimer's Association Research Fellowship, AARF-23-1151259.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data were simulated and the scripts for simulation are available.

https://github.com/Cojabi/inverse_learning

List of abbreviations

AD: Alzheimer’s disease
CR: cognitive resilience

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.